| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9498445 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(9 years from now) | |
| US9050263 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(9 years from now) | |
| US11135172 | REDHILL | Rifabutin-based compositions and methods for treating Helicobacter pylori infection |
Feb, 2034
(9 years from now) | |
| US10238606 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(9 years from now) | |
| US9603806 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(9 years from now) | |
Talicia is owned by Redhill.
Talicia contains Amoxicillin; Omeprazole Magnesium; Rifabutin.
Talicia has a total of 5 drug patents out of which 0 drug patents have expired.
Talicia was authorised for market use on 01 November, 2019.
Talicia is available in capsule, delayed release;oral dosage forms.
Talicia can be used as treatment of h. pylori infection in adults.
The generics of Talicia are possible to be released after 12 February, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 01, 2027 |
Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient
Market Authorisation Date: 01 November, 2019
Treatment: Treatment of h. pylori infection in adults
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TALICIA family patents
